Overview

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

Status:
Completed

Trial end date:
2020-03-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with an oral antipsychotic medication.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Cilag International NV

Treatments:

Paliperidone Palmitate